928 related articles for article (PubMed ID: 30114965)
1. Structure based virtual screening, 3D-QSAR, molecular dynamics and ADMET studies for selection of natural inhibitors against structural and non-structural targets of Chikungunya.
Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
J Biomol Struct Dyn; 2019 Aug; 37(12):3150-3161. PubMed ID: 30114965
[TBL] [Abstract][Full Text] [Related]
2.
Chaudhary M; Sehgal D
J Biomol Struct Dyn; 2022; 40(22):11560-11570. PubMed ID: 34355667
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV.
Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
J Biomol Struct Dyn; 2019 Jan; 37(1):131-146. PubMed ID: 29268664
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling, molecular docking and molecular dynamics simulation for screening and identifying anti-dengue phytocompounds.
Vora J; Patel S; Athar M; Sinha S; Chhabria MT; Jha PC; Shrivastava N
J Biomol Struct Dyn; 2020 Apr; 38(6):1726-1740. PubMed ID: 31057055
[TBL] [Abstract][Full Text] [Related]
5. Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV Agents.
Jadav SS; Sinha BN; Hilgenfeld R; Jayaprakash V
Curr Comput Aided Drug Des; 2017 Nov; 13(4):346-361. PubMed ID: 28294048
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Inhibitor Binding Combined with Reactivity Studies to Discover the Potentially Inhibiting Phytochemicals Targeting Chikungunya Viral Replication.
Rasool N; Bakht A; Hussain W
Curr Drug Discov Technol; 2021; 18(3):437-450. PubMed ID: 32164512
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Peptidomimetics as Irreversible CHIKV NsP2 Protease Inhibitors Using Quantum Mechanical-Based Ligand Descriptors.
El-labbad EM; Ismail MA; Abou Ei Ella DA; Ahmed M; Wang F; Barakat KH; Abouzid KA
Chem Biol Drug Des; 2015 Dec; 86(6):1518-27. PubMed ID: 26212366
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo studies reveal α-Mangostin, a xanthonoid from Garcinia mangostana, as a promising natural antiviral compound against chikungunya virus.
Patil P; Agrawal M; Almelkar S; Jeengar MK; More A; Alagarasu K; Kumar NV; Mainkar PS; Parashar D; Cherian S
Virol J; 2021 Feb; 18(1):47. PubMed ID: 33639977
[TBL] [Abstract][Full Text] [Related]
9. Spectral characterisation, antiviral activities, in silico ADMET and molecular docking of the compounds isolated from Tectona grandis to chikungunya virus.
K S; Purushothaman I; S R
Biomed Pharmacother; 2017 Mar; 87():302-310. PubMed ID: 28063412
[TBL] [Abstract][Full Text] [Related]
10. Discovery of small molecule inhibitors of chikungunya virus proteins (nsP2 and E1) using
Khan N; Bhat R; Patel AK; Ray P
J Biomol Struct Dyn; 2021 Mar; 39(4):1373-1385. PubMed ID: 32072865
[TBL] [Abstract][Full Text] [Related]
11. Antivirals against the Chikungunya Virus.
Battisti V; Urban E; Langer T
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372513
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression.
Kaur P; Thiruchelvan M; Lee RC; Chen H; Chen KC; Ng ML; Chu JJ
Antimicrob Agents Chemother; 2013 Jan; 57(1):155-67. PubMed ID: 23275491
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection.
Ashbrook AW; Lentscher AJ; Zamora PF; Silva LA; May NA; Bauer JA; Morrison TE; Dermody TS
mBio; 2016 May; 7(3):. PubMed ID: 27222471
[TBL] [Abstract][Full Text] [Related]
14. Discovery of in silico hits targeting the nsP3 macro domain of chikungunya virus.
Nguyen PT; Yu H; Keller PA
J Mol Model; 2014 May; 20(5):2216. PubMed ID: 24756552
[TBL] [Abstract][Full Text] [Related]
15. Current Strategies for Inhibition of Chikungunya Infection.
Subudhi BB; Chattopadhyay S; Mishra P; Kumar A
Viruses; 2018 May; 10(5):. PubMed ID: 29751486
[TBL] [Abstract][Full Text] [Related]
16. Drug repurposing approach against chikungunya virus: an
Kasabe B; Ahire G; Patil P; Punekar M; Davuluri KS; Kakade M; Alagarasu K; Parashar D; Cherian S
Front Cell Infect Microbiol; 2023; 13():1132538. PubMed ID: 37180434
[TBL] [Abstract][Full Text] [Related]
17. In silico and in vitro evaluation of silibinin: a promising anti-Chikungunya agent.
Dutta SK; Sengupta S; Tripathi A
In Vitro Cell Dev Biol Anim; 2022 Mar; 58(3):255-267. PubMed ID: 35381943
[TBL] [Abstract][Full Text] [Related]
18. Development of a theoretical model for the inhibition of nsP3 protease of Chikungunya virus using pyranooxazoles.
Kumar D; Kumari K; Jayaraj A; Singh P
J Biomol Struct Dyn; 2020 Jul; 38(10):3018-3034. PubMed ID: 31366291
[TBL] [Abstract][Full Text] [Related]
19. Chikungunya virus drug discovery: still a long way to go?
Pérez-Pérez MJ; Delang L; Ng LFP; Priego EM
Expert Opin Drug Discov; 2019 Sep; 14(9):855-866. PubMed ID: 31177861
[No Abstract] [Full Text] [Related]
20. Antivirals against Chikungunya Virus: Is the Solution in Nature?
Martins DOS; Santos IA; de Oliveira DM; Grosche VR; Jardim ACG
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
